NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- – Bragar Eagel & Squire, P.C., a nationally recognized shareholder…
Investors who purchased Altimmune, Inc. stock between December 1, 2023, and April 26, 2024, have until July 5, 2024, to…
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight…
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune"…
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Earnings call: Altimmune reports progress in pemvidutide trials…
…
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight…
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action…
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.…
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced…
GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and…
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.…
H.C. Wainwright lowers Altimmune stock PT, cites HepTcell program halt…
…
Earnings call: Altimmune reports promising pemvidutide trial results…
The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that…
…
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…